Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.

A third of participants who took Covaxin report adverse events, new study finds

A significant rate of adverse events of special interest (AESI) was reported among participants of Bharat Biotech’s Covid-19 vaccine Covaxin, a new study has revealed.

The study found that nearly a third of participants experienced AESI, according to a report on SpringerLink, an integrated platform for journals and other materials published by Springer.

It is also revealed that adolescent girls and people with a history of allergies are at higher risk of AESI.

The study was conducted by Sankha Shubhra Chakrabarti and her team from Banaras Hindu University. She said: “The majority of AESI persisted after one year of follow-up. »

During the 1-year follow-up, 635 adolescents and 291 adults of the 1,024 people enrolled were contacted. The study further found that 124 (42.6%) adults and 304 (47.9%) adolescents reported having upper respiratory viral infections after taking the vaccine.

The most common AEFIs among adolescents were new-onset skin and subcutaneous disorders (10.5%), general disorders (10.2%), and nervous system disorders (4.7%).

Meanwhile, among adults, common AESIs reported were nervous system disorders (5.5%), musculoskeletal disorders (5.8%), and general disorders (8.9%).

Other problems reported were menstrual abnormalities in 4.6% of participants, eye abnormalities in 2.7%, and hypothyroidism in 0.6% of participants.

Serious AESI such as stroke and Guillain-Barré syndrome were observed in 0.3% and 0.1% of participants, respectively.

The study also indicated that participants with a history of allergy and post-vaccination typhoid had a 1.6, 2.8, and 2.8 times higher risk of AESI, and that the majority of AESI occurs during during a one-year follow-up.

Women and adolescents with a history of COVID-19 before vaccination, comorbidities, or typhoid after vaccination had 1.6, 2, 2.7, and 3.2 times higher risks of persistent AESI. Adults with comorbidities had more than twice the risk of AESI and persistent AESI compared to others.

Adolescents and adults experienced different side effects after receiving Covaxin compared to those seen with other COVID-19 vaccines.

The researchers also highlighted the need for extensive monitoring of people vaccinated against COVID-19 to understand the long-term effects and consequences of these adverse events.

“Targeted surveillance for persistent AESI is warranted for individuals with a history of COVID prior to vaccination,” the researchers said.

“Adults with comorbidities, such as hypertension, are at higher risk of AESI and persistent AESI after BBV152 administration. The patterns of AESI developing after Covaxin differ from those observed after Covishield, as well as within different age groups,” he adds.


Back to top button